FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360976135> ?p ?o ?g. }

• W4360976135 abstract "Multiple cancers are a common occurrence, and the choice of treatment can be a challenging decision. The current case report describes a 71-year-old woman with overlapping anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinoma and HER2-mutant breast cancer, who achieved improvement with concurrent use of the molecularly targeted agents Alectinib, Trastuzumab, and Pertuzumab. A 71-year-old woman was diagnosed with lung adenocarcinoma and brain metastases, and invasive ductal carcinoma of the right breast, HER2-mutant type. In March 2021, a biopsy confirmed the presence of the ALK fusion gene in lung cancer. In April 2021, he started Alectinib and showed shrinkage of lung cancer; in December 2021, a metastatic liver tumor was found, and a liver biopsy diagnosed liver metastasis of breast cancer. Therefore, Alectinib was discontinued in February 2022, and Trastuzumab, Pertuzumab, and Docetaxel were started as chemotherapy for breast cancer. She continued treatment with Trastuzumab and Pertuzumab, but in July 2022, she developed an increase in lung cancer. Her metastatic liver tumor continued shrinking, and she was started on Trastuzumab, Pertuzumab, and Alectinib. After six months of treatment, the patient showed a sustained reduction in both lung cancer, breast cancer, and brain metastases with no adverse events. ALK rearrangement lung cancer often develops in young women, and similarly, breast cancer often develops in women. Therefore, those cancers may occur simultaneously. In such cases, the choice of treatment can be difficult, as both cancers require different approaches. Alectinib has been shown to have a high response rate and prolonged progression-free survival in ALK-rearranged non-small cell lung cancer (NSCLC). Trastuzumab and Pertuzumab are commonly used for the treatment of HER2-mutant breast cancer and have been shown to significantly improve progression-free survival and overall survival. This case report provides evidence that the concurrent use of Alectinib, Trastuzumab, and Pertuzumab can be an effective treatment for patients with overlapping ALK-rearranged NSCLC and HER2-mutant breast cancer. It is important to consider concurrent treatment in patients with multiple cancers to optimize treatment outcomes and improve quality of life. However, further studies are needed to establish the safety and efficacy of this combination of drugs for the treatment of overlapping cancers." @default.
• W4360976135 created "2023-03-30" @default.
• W4360976135 creator A5024548116 @default.
• W4360976135 creator A5049407102 @default.
• W4360976135 creator A5054367448 @default.
• W4360976135 creator A5072112131 @default.
• W4360976135 creator A5087394984 @default.
• W4360976135 date "2023-03-26" @default.
• W4360976135 modified "2023-10-14" @default.
• W4360976135 title "ALK-Rearranged NSCLC With Concomitant HER2-Mutant Breast Cancer Patient Treated With Alectinib, Trastuzumab, and Pertuzumab: A Case Report" @default.
• W4360976135 cites W2055402151 @default.
• W4360976135 cites W2065477010 @default.
• W4360976135 cites W2066417528 @default.
• W4360976135 cites W2099530756 @default.
• W4360976135 cites W2123727052 @default.
• W4360976135 cites W2141393790 @default.
• W4360976135 cites W2624310346 @default.
• W4360976135 cites W2624590002 @default.
• W4360976135 cites W2917906670 @default.
• W4360976135 cites W3016506404 @default.
• W4360976135 cites W3126817559 @default.
• W4360976135 cites W3201219318 @default.
• W4360976135 cites W4295066563 @default.
• W4360976135 doi "https://doi.org/10.7759/cureus.36711" @default.
• W4360976135 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37113357" @default.
• W4360976135 hasPublicationYear "2023" @default.
• W4360976135 type Work @default.
• W4360976135 citedByCount "0" @default.
• W4360976135 crossrefType "journal-article" @default.
• W4360976135 hasAuthorship W4360976135A5024548116 @default.
• W4360976135 hasAuthorship W4360976135A5049407102 @default.
• W4360976135 hasAuthorship W4360976135A5054367448 @default.
• W4360976135 hasAuthorship W4360976135A5072112131 @default.
• W4360976135 hasAuthorship W4360976135A5087394984 @default.
• W4360976135 hasBestOaLocation W43609761351 @default.
• W4360976135 hasConcept C117643217 @default.
• W4360976135 hasConcept C121608353 @default.
• W4360976135 hasConcept C126322002 @default.
• W4360976135 hasConcept C143998085 @default.
• W4360976135 hasConcept C2776232967 @default.
• W4360976135 hasConcept C2776256026 @default.
• W4360976135 hasConcept C2779220645 @default.
• W4360976135 hasConcept C2779422266 @default.
• W4360976135 hasConcept C2779786085 @default.
• W4360976135 hasConcept C2781164504 @default.
• W4360976135 hasConcept C2781182431 @default.
• W4360976135 hasConcept C2781190966 @default.
• W4360976135 hasConcept C530470458 @default.
• W4360976135 hasConcept C71924100 @default.
• W4360976135 hasConceptScore W4360976135C117643217 @default.
• W4360976135 hasConceptScore W4360976135C121608353 @default.
• W4360976135 hasConceptScore W4360976135C126322002 @default.
• W4360976135 hasConceptScore W4360976135C143998085 @default.
• W4360976135 hasConceptScore W4360976135C2776232967 @default.
• W4360976135 hasConceptScore W4360976135C2776256026 @default.
• W4360976135 hasConceptScore W4360976135C2779220645 @default.
• W4360976135 hasConceptScore W4360976135C2779422266 @default.
• W4360976135 hasConceptScore W4360976135C2779786085 @default.
• W4360976135 hasConceptScore W4360976135C2781164504 @default.
• W4360976135 hasConceptScore W4360976135C2781182431 @default.
• W4360976135 hasConceptScore W4360976135C2781190966 @default.
• W4360976135 hasConceptScore W4360976135C530470458 @default.
• W4360976135 hasConceptScore W4360976135C71924100 @default.
• W4360976135 hasLocation W43609761351 @default.
• W4360976135 hasLocation W43609761352 @default.
• W4360976135 hasLocation W43609761353 @default.
• W4360976135 hasOpenAccess W4360976135 @default.
• W4360976135 hasPrimaryLocation W43609761351 @default.
• W4360976135 hasRelatedWork W2137228442 @default.
• W4360976135 hasRelatedWork W2343994751 @default.
• W4360976135 hasRelatedWork W2400744927 @default.
• W4360976135 hasRelatedWork W2540085961 @default.
• W4360976135 hasRelatedWork W2587365770 @default.
• W4360976135 hasRelatedWork W2624310346 @default.
• W4360976135 hasRelatedWork W2900007630 @default.
• W4360976135 hasRelatedWork W2941535758 @default.
• W4360976135 hasRelatedWork W3031648518 @default.
• W4360976135 hasRelatedWork W3199005851 @default.
• W4360976135 isParatext "false" @default.
• W4360976135 isRetracted "false" @default.
• W4360976135 workType "article" @default.